Nuclear Translocation of Epidermal Growth Factor Receptor by Akt-dependent Phosphorylation Enhances Breast Cancer-resistant Protein Expression in Gefitinib-resistant Cells-Reference-Cited by-同舟云学术

Nuclear Translocation of Epidermal Growth Factor Receptor by Akt-dependent Phosphorylation Enhances Breast Cancer-resistant Protein Expression in Gefitinib-resistant Cells

Published:2011-06 Issue:23 Volume:286 Page:20558-20568
ISSN:0021-9258
Container-title:Journal of Biological Chemistry
language:en
Short-container-title:Journal of Biological Chemistry

Author:

Huang Wei-Chien,Chen Yun-Ju,Li Long-Yuan,Wei Ya-Ling,Hsu Sheng-Chieh,Tsai Shing-Ling,Chiu Pei-Chun,Huang Wei-Pang,Wang Ying-Nai,Chen Chung-Hsuan,Chang Wei-Chao,Chang Wen-Chang,Chen Andy Jer-En,Tsai Chang-Hai,Hung Mien-Chie

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry

Reference62 articles.

1. ERBB receptors and cancer: the complexity of targeted inhibitors

2. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

3. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

4. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

5. Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors

Cited by 147 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Non-Canonical p75HER2 Signaling Pathway Underlying Trastuzumab Action and Resistance in Breast Cancer;Cells;2024-08-29

2. Targeted blocking of EGFR and GLUT1 by compound H reveals a new strategy for treatment of triple-negative breast cancer and nasopharyngeal carcinoma;European Journal of Pharmaceutical Sciences;2024-07

3. Therapeutic implications of signaling pathways and tumor microenvironment interactions in esophageal cancer;Biomedicine & Pharmacotherapy;2024-07

4. p53 modulates kinase inhibitor resistance and lineage plasticity in NF1-related MPNSTs;Oncogene;2024-03-13

5. YES1 as a potential target to overcome drug resistance in EGFR-deregulated non-small cell lung cancer;Archives of Toxicology;2024-03-05